TherapeuticsMD, Inc. (TXMD)
USD 1.1
(-3.51%)
USD 1.1
(-3.51%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 8 Million USD | -8.61% |
| 2022 | 8.75 Million USD | -95.54% |
| 2021 | 196.33 Million USD | -20.31% |
| 2020 | 246.37 Million USD | 20.9% |
| 2019 | 203.77 Million USD | 177.7% |
| 2018 | 73.38 Million USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | -100.0% |
| 2012 | 3.58 Million USD | 66.94% |
| 2011 | 2.15 Million USD | 185.32% |
| 2010 | 753.53 Thousand USD | 25.59% |
| 2009 | 600 Thousand USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | -100.0% |
| 2005 | 81.82 Thousand USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | 0.0% |
| 1999 | - USD | -100.0% |
| 1998 | 23.36 Thousand USD | 0.0% |
| 1997 | - USD | 0.0% |
| 1996 | - USD | -100.0% |
| 1995 | 50 Thousand USD | 0.0% |
| 1994 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 7.8 Million USD | -2.54% |
| 2024 Q2 | 7.59 Million USD | -2.68% |
| 2023 Q2 | 8.38 Million USD | -2.2% |
| 2023 FY | 8 Million USD | -8.61% |
| 2023 Q1 | 8.57 Million USD | -2.09% |
| 2023 Q3 | 8.2 Million USD | -2.18% |
| 2023 Q4 | 8 Million USD | -2.43% |
| 2022 Q4 | 8.75 Million USD | -91.46% |
| 2022 Q3 | 102.53 Million USD | 2.66% |
| 2022 Q2 | 99.88 Million USD | -52.91% |
| 2022 FY | 8.75 Million USD | -95.54% |
| 2022 Q1 | 212.12 Million USD | 8.04% |
| 2021 Q2 | 193.64 Million USD | 0.59% |
| 2021 FY | 196.33 Million USD | -20.31% |
| 2021 Q3 | 194.96 Million USD | 0.68% |
| 2021 Q1 | 192.5 Million USD | -21.87% |
| 2021 Q4 | 196.33 Million USD | 0.7% |
| 2020 Q2 | 253.1 Million USD | -0.34% |
| 2020 Q1 | 253.96 Million USD | 24.63% |
| 2020 Q3 | 245.95 Million USD | -2.82% |
| 2020 Q4 | 246.37 Million USD | 0.17% |
| 2020 FY | 246.37 Million USD | 20.9% |
| 2019 Q2 | 196.58 Million USD | 157.9% |
| 2019 FY | 203.77 Million USD | 177.7% |
| 2019 Q1 | 76.22 Million USD | 3.88% |
| 2019 Q4 | 203.77 Million USD | -0.04% |
| 2019 Q3 | 203.86 Million USD | 3.7% |
| 2018 Q2 | 73.14 Million USD | 0.0% |
| 2018 Q3 | 73.26 Million USD | 0.16% |
| 2018 Q4 | 73.38 Million USD | 0.16% |
| 2018 Q1 | - USD | 0.0% |
| 2018 FY | 73.38 Million USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 FY | - USD | -100.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q2 | - USD | -100.0% |
| 2013 Q1 | 100 Thousand USD | -97.21% |
| 2012 Q2 | 3.54 Million USD | -0.48% |
| 2012 FY | 3.58 Million USD | 66.94% |
| 2012 Q1 | 3.56 Million USD | 65.61% |
| 2012 Q3 | 5.59 Million USD | 57.78% |
| 2012 Q4 | 3.58 Million USD | -35.8% |
| 2011 FY | 2.15 Million USD | 185.32% |
| 2011 Q4 | 2.15 Million USD | 489.04% |
| 2011 Q3 | 365 Thousand USD | 18.12% |
| 2011 Q2 | 309 Thousand USD | 29.29% |
| 2011 Q1 | 239 Thousand USD | -68.28% |
| 2010 Q2 | - USD | -100.0% |
| 2010 FY | 753.53 Thousand USD | 25.59% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q4 | 753.53 Thousand USD | 0.0% |
| 2010 Q1 | 800 Thousand USD | 33.33% |
| 2009 FY | 600 Thousand USD | 0.0% |
| 2009 Q3 | 300 Thousand USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 Q4 | 600 Thousand USD | 100.0% |
| 2009 Q1 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2006 Q4 | - USD | -100.0% |
| 2006 Q3 | 86.22 Thousand USD | 1.73% |
| 2006 FY | - USD | -100.0% |
| 2006 Q2 | 84.76 Thousand USD | 1.76% |
| 2006 Q1 | 83.29 Thousand USD | 1.79% |
| 2005 Q4 | 81.82 Thousand USD | 39.54% |
| 2005 Q1 | - USD | 0.0% |
| 2005 FY | 81.82 Thousand USD | 0.0% |
| 2005 Q3 | 58.64 Thousand USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2001 Q4 | - USD | 0.0% |
| 2001 Q1 | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2000 Q4 | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 Q1 | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| 1999 Q4 | - USD | 0.0% |
| 1999 FY | - USD | -100.0% |
| 1998 FY | 23.36 Thousand USD | 0.0% |
| 1997 FY | - USD | 0.0% |
| 1996 FY | - USD | -100.0% |
| 1995 FY | 50 Thousand USD | 0.0% |
| 1994 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Theratechnologies Inc. | 58.96 Million USD | 86.425% |
| Harrow Health, Inc. | 190.5 Million USD | 95.798% |
| Dynavax Technologies Corporation | 256.91 Million USD | 96.884% |
| Biofrontera Inc. | 5.39 Million USD | -48.268% |
| Cronos Group Inc. | 2.53 Million USD | -215.165% |
| Sonoma Pharmaceuticals, Inc. | 608 Thousand USD | -1216.612% |
| Ironwood Pharmaceuticals, Inc. | 715.53 Million USD | 98.881% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | 77.962% |
| RedHill Biopharma Ltd. | 1.17 Million USD | -582.435% |
| Cumberland Pharmaceuticals Inc. | 18.42 Million USD | 56.562% |
| Radius Health, Inc. | 365.31 Million USD | 97.809% |
| Universe Pharmaceuticals INC | 5.48 Million USD | -46.011% |
| DURECT Corporation | 20.74 Million USD | 61.414% |
| ProPhase Labs, Inc. | 21.38 Million USD | 62.558% |
| Safety Shot Inc | 1.54 Million USD | -416.794% |
| Phibro Animal Health Corporation | 525.45 Million USD | 98.477% |
| China SXT Pharmaceuticals, Inc. | 2.64 Million USD | -202.366% |
| Alvotech | 1.07 Billion USD | 99.256% |
| Assertio Holdings, Inc. | 40.91 Million USD | 80.434% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | 80.723% |
| Rockwell Medical, Inc. | 13.43 Million USD | 40.435% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | -1117.111% |
| Procaps Group S.A. | 285.93 Million USD | 97.2% |
| Intra-Cellular Therapies, Inc. | 16.93 Million USD | 52.739% |
| SCYNEXIS, Inc. | 15.08 Million USD | 46.916% |
| Aytu BioPharma, Inc. | 15.12 Million USD | 47.088% |
| Viatris Inc. | 18.12 Billion USD | 99.956% |
| OptiNose, Inc. | 131.74 Million USD | 93.924% |
| SIGA Technologies, Inc. | 1.46 Million USD | -446.786% |
| Tilray Brands, Inc. | 387.31 Million USD | 97.933% |
| PetIQ, Inc. | 468.3 Million USD | 98.291% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | -1117.111% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | 98.131% |
| Guardion Health Sciences, Inc. | - USD | -Infinity% |
| Alimera Sciences, Inc. | 67.39 Million USD | 88.123% |
| Collegium Pharmaceutical, Inc. | 674.28 Million USD | 98.813% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.08 Million USD | -635.961% |
| Organogenesis Holdings Inc. | 119.35 Million USD | 93.293% |
| Journey Medical Corporation | 17.73 Million USD | 54.851% |
| Petros Pharmaceuticals, Inc. | 8.27 Million USD | 3.281% |
| Alpha Teknova, Inc. | 30.45 Million USD | 73.718% |
| Clever Leaves Holdings Inc. | 2.08 Million USD | -283.565% |
| Lifecore Biomedical, Inc. | 130.36 Million USD | 93.859% |
| PainReform Ltd. | 86 Thousand USD | -9208.14% |
| Cosmos Health Inc. | 12.42 Million USD | 35.568% |
| Avadel Pharmaceuticals plc | 35.38 Million USD | 77.377% |
| Embecta Corp. | 1.63 Billion USD | 99.511% |
| Regencell Bioscience Holdings Limited | 59.8 Thousand USD | -13284.721% |
| Talphera, Inc. | - USD | -Infinity% |
| Pacira BioSciences, Inc. | 586.04 Million USD | 98.634% |
| Incannex Healthcare Limited | 373 Thousand USD | -2046.113% |
| Cyclo Therapeutics, Inc. | 1.03 Million USD | -674.841% |
| Shineco, Inc. | 29.65 Million USD | 73.008% |
| Procaps Group, S.A. | 285.93 Million USD | 97.2% |
| ANI Pharmaceuticals, Inc. | 315.32 Million USD | 97.461% |
| Aquestive Therapeutics, Inc. | 98.82 Million USD | 91.9% |
| Lantheus Holdings, Inc. | 616.94 Million USD | 98.702% |
| Alvotech | 1.07 Billion USD | 99.256% |
| Hempacco Co., Inc. | 13.72 Million USD | 41.674% |
| Eagle Pharmaceuticals, Inc. | 62.46 Million USD | 87.185% |
| Bright Green Corporation | 1.85 Million USD | -332.286% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | 98.52% |
| Kamada Ltd. | 8.74 Million USD | 8.504% |
| Indivior PLC | 281.6 Million USD | 97.157% |
| Evoke Pharma, Inc. | 5 Million USD | -60.1% |
| Flora Growth Corp. | 3.67 Million USD | -118.001% |
| Cyclo Therapeutics, Inc. | 1.03 Million USD | -674.841% |
| Evolus, Inc. | 126.54 Million USD | 93.674% |
| HUTCHMED (China) Limited | 86.13 Million USD | 90.706% |
| Amphastar Pharmaceuticals, Inc. | 623.64 Million USD | 98.716% |
| Akanda Corp. | 3.99 Million USD | -100.186% |